Results of a prospective phase II randomized study of deferasirox (Exjade) to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia (HREC/10/QRBW/135)

• Kennedy GA
• Morris K
• Pillai E
• Curley C
• Butler JP
• Durrant S